USP Compounding Standards (795 · 797 · 825)
Non-sterile, sterile, and radiopharmaceutical-specific compounding chapters
Quick Answer
Three USP chapters govern how drugs are compounded: ⟨795⟩ non-sterile, ⟨797⟩ sterile, and ⟨825⟩ radiopharmaceuticals — the chapter written specifically for nuclear pharmacy. USP ⟨825⟩ is the controlling standard for preparing, compounding, dispensing, and repackaging radiopharmaceuticals, harmonizing sterility/quality with the realities of short half-lives and radiation safety (it recognizes that release often precedes full sterility testing and balances ALARA against aseptic technique). It defines beyond-use dates (BUDs), air-quality/engineering-control requirements, and categories such as immediate-use preparation.
Why a Radiopharmaceutical-Specific Chapter
General sterile-compounding rules (⟨797⟩) assume time for sterility testing and don't address radiation. Radiopharmaceuticals are short-lived (a Tc-99m or F-18 dose can't wait days for sterility results) and radioactive (ALARA competes with prolonged aseptic manipulation). ⟨825⟩ was created to reconcile these — it applies sterile-compounding principles while accommodating decay and radiation safety, and it is the standard nuclear pharmacy follows.
The Three Chapters
| Chapter | Scope | Key concepts |
|---|---|---|
| ⟨795⟩ | Non-sterile compounding | Category-based BUDs, ingredient/quality standards |
| ⟨797⟩ | Sterile compounding | Air quality (ISO classes), PEC/SEC, garbing, media-fill, microbial BUD limits |
| ⟨825⟩ | Radiopharmaceuticals | Sterile principles + radiation safety, decay, immediate-use, repackaging/elution, generator handling |
A related chapter — not a compounding one. USP ⟨800⟩ (Hazardous Drugs — Handling in Healthcare Settings) governs containment and handling, not compounding, so it is not one of the three compounding chapters above. It still applies to radiopharmaceuticals that are also hazardous drugs (e.g. some therapy agents), and is considered alongside ⟨825⟩ for those.
Core ⟨825⟩ Concepts
- Categories of activity: preparation (per manufacturer kit instructions), compounding (altering/combining beyond labeling), dispensing, and repackaging — each with requirements.
- Immediate-use provisions for urgent, short-turnaround doses (limited, defined conditions).
- Engineering controls: appropriate primary engineering control (PEC) and shielded workspace; air quality suited to the manipulation.
- Beyond-use dating (BUD): the date/time after which a preparation must not be used — driven by sterility risk and radiochemical stability, alongside physical decay.
- Quality/QC: radiochemical/radionuclidic purity, and documentation, integrated with radiation-safety practice.
Beyond-Use Date vs Expiration
BUD is assigned by the compounder based on stability and sterility risk of the specific preparation; a manufacturer expiration date applies to the original product. For radiopharmaceuticals, the usable window is often bounded by decay as much as sterility.
Practice Notes
- Follow ⟨825⟩ as the operative standard for radiopharmaceutical preparation/compounding; use ⟨797⟩ principles for asepsis and ⟨795⟩ for any non-sterile components.
- Match engineering controls and air quality to the manipulation performed.
- Assign and document BUDs; integrate ALARA with aseptic technique.
Common Pitfalls
- Applying ⟨797⟩ alone to radiopharmaceuticals without ⟨825⟩'s radiation/decay accommodations.
- Confusing BUD (compounder-assigned, stability/sterility) with manufacturer expiration.
- Overlooking immediate-use conditions/limits.
- Ignoring ⟨800⟩ for radiopharmaceuticals that are also hazardous drugs.
Board Pearls
Three USP chapters govern compounding — ⟨795⟩ non-sterile, ⟨797⟩ sterile, ⟨825⟩ radiopharmaceuticals — and ⟨825⟩ is the controlling standard for radiopharmaceutical preparation/compounding/dispensing/repackaging. It exists because general sterile rules assume time for sterility testing and ignore radiation, whereas radiopharmaceuticals are short-lived (release often precedes full testing) and radioactive (ALARA vs prolonged asepsis).
A beyond-use date (BUD) is assigned by the compounder from stability/sterility risk (distinct from the manufacturer's expiration); for radiopharmaceuticals the window is often bounded by decay. Immediate-use provisions allow urgent short-turnaround doses under defined limits.
⟨825⟩ distinguishes preparation (per kit instructions), compounding (beyond labeling), dispensing, and repackaging, each with engineering-control and air-quality requirements matched to the manipulation. Radiopharmaceuticals that are also hazardous drugs additionally invoke ⟨800⟩ containment.
Related Pages
- Physics: Radiation biology & protection; radiopharmacy: PET radiochemistry & production; safety: Radiation safety & patient release.
Figure / Diagram Suggestions
- A 795/797/825 scope Venn (non-sterile / sterile / radiopharmaceutical, with 800 overlap).
- A BUD-vs-expiration-vs-decay timeline for a Tc-99m dose.
Self-Check
Q1. Which USP chapter is the controlling standard for radiopharmaceutical compounding, and why does it exist separately?
Answer: ⟨825⟩ — general sterile rules (⟨797⟩) assume time for sterility testing and ignore radiation, but radiopharmaceuticals are short-lived (release precedes full testing) and radioactive (ALARA vs prolonged asepsis).
Q2. Distinguish a beyond-use date (BUD) from a manufacturer expiration date.
Answer: A BUD is assigned by the compounder based on stability/sterility risk of the specific preparation; an expiration date applies to the original manufactured product (for radiopharmaceuticals, decay often bounds the usable window).
Q3. Match: ⟨795⟩, ⟨797⟩, ⟨825⟩.
Answer: ⟨795⟩ non-sterile, ⟨797⟩ sterile, ⟨825⟩ radiopharmaceuticals.
Q4. Name two activity categories ⟨825⟩ distinguishes.
Answer: Any two of preparation (per kit instructions), compounding (beyond labeling), dispensing, and repackaging.
Evidence & sources
https://nuc.med/usp-compounding-standards/ Report an issue